Assessing the efficacy of cannabinoids in managing cannabis use disorder: A systematic review of randomized controlled trials with pharmacological emphasis
Mari Yamada Camila , Valeriano Zamora Fernanda , Clara Felix de Farias Santos Ana , Almeida Jacob Moreno Patrícia , dos Santos Pimenta Nicole , Pedro Costa Esteves Almuinha Salles Joao , Kerley Capuchinho Scalioni Galvao Lorhayne , Antunes do Livramento Junior Vânio , Villca Zamora Andres
Journal of Clinical and Translational Research ›› 2025, Vol. 11 ›› Issue (1) : 4 -14.
Assessing the efficacy of cannabinoids in managing cannabis use disorder: A systematic review of randomized controlled trials with pharmacological emphasis
Background: Cannabis is the most used illicit drug worldwide. The increasing prevalence of cannabis use has raised concerns about the development of cannabis use disorder (CUD) and cannabis withdrawal syndrome (CWS). Thus far, however, no medications have been proven effective for treating these conditions. In this context, several cannabinoid (CB) preparations are being investigated as potential treatments. Aim: This systematic review aims to provide an overview of the key findings from medical CBs in the management of CUD and CWS, focusing on the efficacy of and users’ tolerability to different CB formulations. Conclusion: The findings suggest that certain CB preparations, such as nabiximols and cannabidiol, may effectively reduce cannabis use and enhance abstinence rates, providing hope for patients struggling with CUD. Conversely, CB receptor agonists such as dronabinol and nabilone show limited therapeutic potential, indicating the need for further research to identify effective treatments for cannabis dependence. Relevance for patients: These findings offer potential treatment options to help patients reduce cannabis use and improve abstinence from cannabis dependence.
Cannabis use disorder / Cannabinoids / Cannabis withdrawal syndrome
/
| 〈 |
|
〉 |
PDF
